Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals
We previously reported that galectin-9 (Gal-9), a soluble lectin with immunomodulatory properties, is elevated in plasma during HIV infection and induces HIV transcription. The link between Gal-9 and compromised neuronal function is becoming increasingly evident; however, the association with neuroHIV remains unknown. We measured Gal-9 levels by ELISA in cerebrospinal fluid (CSF) and plasma of 70 HIV-infected (HIV+) adults stratified by age (older > 40 years and younger < 40 years) either ART suppressed or with detectable CSF HIV RNA, including a subgroup with cognitive assessments, and 18 HIV uninfected (HIV−) controls. Gal-9 tissue expression was compared in necropsy brain specimens from HIV− and HIV+ donors using gene datasets and immunohistochemistry. Among older HIV+ adults, CSF Gal-9 was elevated in the ART suppressed and CSF viremic groups compared to controls, whereas in the younger group, Gal-9 levels were elevated only in the CSF viremic group (p < 0.05). CSF Gal-9 positively correlated with age in all groups (p < 0.05). CSF Gal-9 tracked with CSF HIV RNA irrespective of age (β = 0.33; p < 0.05). Higher CSF Gal-9 in the older viremic HIV+ group correlated with worse neuropsychological test performance scores independently of age and CSF HIV RNA (p < 0.05). Furthermore, CSF Gal-9 directly correlated with myeloid activation (CSF-soluble CD163 and neopterin) in both HIV+ older groups (p < 0.05). Among HIV+ necropsy specimens, Gal-9 expression was increased in select brain regions compared to controls (p < 0.05). Gal-9 may serve as a novel neuroimmuno-modulatory protein that is involved in driving cognitive deficits in those aging with HIV and may be valuable in tracking cognitive abnormalities.
KeywordsGalectin-9 HIV Biomarkers Neuroinflammation Cognitive disorders
We thank all study participants and study groups, Scott Bowler for his help with specimen management, and Vedbar Khadka, Daniel Laspisa, and Lindsay Kohorn for their guidance with data analysis.
TAP and LCN drafted the manuscript. TAP performed all soluble analyte quantifications and data analyses. LCN conceived the design of the study and coordinated the integration of collaboration between all participating groups. MAM and SKP aided in the study design. BS and MAG conducted HIV DNA quantifications. VV, CMS, RKP, and MG designed the study cohorts and acquisition of participant demographic and clinical data. BKN and KK assisted with interpreting clinical and diagnostic data. VV, BS, MAM, and MLD provided critical analysis of the manuscript. All authors critically reviewed and edited the final version of the manuscript.
This work was supported in part by National Institutes of Health (NIH) grants 1R01MH112457-01 (LCN and SP), U54NS43049 (CS), MH098759 (VV), R01 NS094067 (RWP), P01 DA026134 (RWP, Project PI), and the Swedish State support for Clinical Research (ALFGBG-717531). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This publication was also made possible by NIH funding through the NIMH and NINDS institutes by the following grants: Texas NeuroAIDS Research Center: U24MH100930, California NeuroAIDS Tissue Network: U24MH100928, National Neurological AIDS Bank: U24MH100929, Manhattan HIV Brain Bank: U24MH100931, and Data Coordinating Center: U24MH100925. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NNTC or NIH.
Compliance with ethical standards
Ethics approval and consent to participate
Informed consent was obtained from participants following procedures approved by the University of Hawai’i Human Studies Institutional Review Board, UCSF Committee on Human Research, and the Regional Ethics Review Board in Gothenburg.
Conflict of interest
The authors declare that they have no competing interests.
- Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK (2015) Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS 29(4):411–420. https://doi.org/10.1097/QAD.0000000000000572 CrossRefPubMedPubMedCentralGoogle Scholar
- Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, Keating S, Lanteri M, Samuels ML, Hoh R, Sacha JB, Norris PJ, Niki T, Shikuma CM, Hirashima M, Deeks SG, Ndhlovu LC, Pillai SK (2016) Human galectin-9 is a potent mediator of HIV transcription and reactivation. PLoS Pathog 12(6):e1005677. https://doi.org/10.1371/journal.ppat.1005677 CrossRefPubMedPubMedCentralGoogle Scholar
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8b CrossRefPubMedPubMedCentralGoogle Scholar
- Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, Saita N, Toyama Y, Takashima H, Nakamura T, Ohkawa M, Hirashima M (2002) Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol 169(10):5912–5918CrossRefGoogle Scholar
- Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, Transidico P, Vagani A, Sozzani S, Mantovani A, Lazzarin A, Poli G (1998) Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12(11):1327–1332CrossRefGoogle Scholar
- Coban H, Robertson K, Smurzynski M, Krishnan S, Wu K, Bosch RJ, Collier AC, Ellis RJ (2017) Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. AIDS 31(11):1565–1571. https://doi.org/10.1097/QAD.0000000000001523 CrossRefPubMedPubMedCentralGoogle Scholar
- Cole JH, Caan MWA, Underwood J, De Francesco D, van Zoest RA, Wit F et al (2018) No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS (COBRA) project. Clin Infect Dis 66(12):1899–1909. https://doi.org/10.1093/cid/cix1124 CrossRefPubMedGoogle Scholar
- D'Antoni ML, Paul RH, Mitchell BI, Kohorn L, Fischer L, Lefebvre E et al (2018a) Improved cognitive performance and reduced monocyte activation in virally suppressed chronic HIV following dual CCR2 and CCR5 antagonism. J Acquir Immune Defic Syndr 79:108–116. https://doi.org/10.1097/QAI.0000000000001752 CrossRefPubMedGoogle Scholar
- D'Antoni ML, Byron MM, Chan P, Sailasuta N, Sacdalan C, Sithinamsuwan P et al (2018b) Normalization of soluble CD163 levels after institution of antiretroviral therapy during acute HIV infection tracks with fewer neurological abnormalities. J Infect Dis 218(9):1453–1463. https://doi.org/10.1093/infdis/jiy337 CrossRefPubMedGoogle Scholar
- de la Fuente H, Perez-Gala S, Bonay P, Cruz-Adalia A, Cibrian D, Sanchez-Cuellar S, Dauden E, Fresno M, García-Diez A, Sanchez-Madrid F (2012) Psoriasis in humans is associated with down-regulation of galectins in dendritic cells. J Pathol 228(2):193–203. https://doi.org/10.1002/path.3996 CrossRefPubMedGoogle Scholar
- Duffau P, Ozanne A, Bonnet F, Lazaro E, Cazanave C, Blanco P, Rivière E, Desclaux A, Hyernard C, Gensous N, Pellegrin I, Wittkop L (2018) Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults. AIDS 32:1651–1660. https://doi.org/10.1097/QAD.0000000000001875 CrossRefPubMedGoogle Scholar
- Eden A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D et al (2016) Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One 11(6):e0157160. https://doi.org/10.1371/journal.pone.0157160 CrossRefPubMedPubMedCentralGoogle Scholar
- Ellis RJ, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, Heyes MP, McCutchan JA, Hampton Atkinson J, Grant I (1998) Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). Neurosci Lett 254(1):1–4CrossRefGoogle Scholar
- Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ (2016) Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 30(4):591–600. https://doi.org/10.1097/QAD.0000000000000951 CrossRefPubMedGoogle Scholar
- Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, Price RW, Fuchs D (2010) Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 7:15. https://doi.org/10.1186/1742-6405-7-15 CrossRefPubMedPubMedCentralGoogle Scholar
- Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F et al (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75(23):2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727 CrossRefPubMedPubMedCentralGoogle Scholar
- Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid. beta Sci Transl Med 4(147):147ra11. https://doi.org/10.1126/scitranslmed.3003748 CrossRefGoogle Scholar
- Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, Nishi N, Fujimoto K, Tanji K, Shibata T, Tamo W, Matsumiya T, Yoshida H, Cui XF, Takanashi S, Hanada K, Okumura K, Yagihashi S, Wakabayashi K, Nakamura T, Hirashima M, Satoh K (2002) Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 72(3):486–491PubMedGoogle Scholar
- Kurose Y, Wada J, Kanzaki M, Teshigawara S, Nakatsuka A, Murakami K, Inoue K, Terami T, Katayama A, Watanabe M, Higuchi C, Eguchi J, Miyatake N, Makino H (2013) Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol 14:23. https://doi.org/10.1186/1471-2369-14-23 CrossRefPubMedPubMedCentralGoogle Scholar
- Kusao I, Shiramizu B, Liang CY, Grove J, Agsalda M, Troelstrup D, Velasco VN, Marshall A, Whitenack N, Shikuma C, Valcour V (2012) Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatr Clin Neurosci 24(1):71–80. https://doi.org/10.1176/appi.neuropsych.11050109 CrossRefGoogle Scholar
- Lerman BJ, Hoffman EP, Sutherland ML, Bouri K, Hsu DK, Liu FT, Rothstein JD, Knoblach SM (2012) Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav 2(5):563–575. https://doi.org/10.1002/brb3.75 CrossRefPubMedPubMedCentralGoogle Scholar
- Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M (2007) Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 69(15):1536–1541. https://doi.org/10.1212/01.wnl.0000277635.05973.55 CrossRefPubMedGoogle Scholar
- Nakamoto BK, Valcour VG, Kallianpur K, Liang CY, McMurtray A, Chow D, Kappenburg E, Shikuma CM (2011) Impact of cerebrovascular disease on cognitive function in HIV-infected patients. J Acquir Immune Defic Syndr 57(3):e66–e68. https://doi.org/10.1097/QAI.0b013e31821ff8bd CrossRefPubMedPubMedCentralGoogle Scholar
- Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM (2014) Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neuro-Oncol 20(6):571–582. https://doi.org/10.1007/s13365-014-0279-x CrossRefGoogle Scholar
- Parikh NU, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Mammen MJ, Schwartz SA, Mahajan SD (2015) Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: Neuroprotective role in maintaining blood brain barrier integrity. Brain Res 1624:175–187. https://doi.org/10.1016/j.brainres.2015.07.033 CrossRefPubMedPubMedCentralGoogle Scholar
- Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, Robertson K, Hagberg L, Zetterberg H, Gisslen M, Spudich S (2013) Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 207(11):1703–1712. https://doi.org/10.1093/infdis/jit088 CrossRefPubMedPubMedCentralGoogle Scholar
- Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, Yiannoutsos CT, Spudich SS, Price RW (2014) Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One 9(12):e116081. https://doi.org/10.1371/journal.pone.0116081 CrossRefPubMedPubMedCentralGoogle Scholar
- Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslén M, Spudich S (2017) Blood-brain barrier disruption is initiated during primary HIV infection and not rapidly altered by antiretroviral therapy. J Infect Dis 215(7):1132–1140. https://doi.org/10.1093/infdis/jix013 CrossRefPubMedPubMedCentralGoogle Scholar
- Sakaguchi M, Shingo T, Shimazaki T, Okano HJ, Shiwa M, Ishibashi S, Oguro H, Ninomiya M, Kadoya T, Horie H, Shibuya A, Mizusawa H, Poirier F, Nakauchi H, Sawamoto K, Okano H (2006) A carbohydrate-binding protein, galectin-1, promotes proliferation of adult neural stem cells. Proc Natl Acad Sci U S A 103(18):7112–7117. https://doi.org/10.1073/pnas.0508793103 CrossRefPubMedPubMedCentralGoogle Scholar
- Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P, for the AGEhIV Cohort Study Group, Reiss P, Wit FWNM, van der Valk M, Schouten J, Kooij KW, van Zoest RA, Elsenga BC, Prins M, Stolte IG, Martens M, Moll S, Berkel J, Moller L, Visser GR, Welling C, Zaheri S, Hillebregt MMJ, Gras LAJ, Ruijs YMC, Benschop DP, Reiss P, Kootstra NA, Harskamp-Holwerda AM, Maurer I, Mangas Ruiz MM, Girigorie AF, van Leeuwen E, Janssen FR, Heidenrijk M, Schrijver JHN, Zikkenheiner W, Wezel M, Jansen-Kok CSM, Geerlings SE, Godfried MH, Goorhuis A, van der Meer JTM, Nellen FJB, van der Poll T, Prins JM, Reiss P, van der Valk M, Wiersinga WJ, Wit FWNM, van Eden J, Henderiks A, van Hes AMH, Mutschelknauss M, Nobel HE, Pijnappel FJJ, Westerman AM, de Jong J, Postema PG, Bisschop PHLT, Serlie MJM, Lips P, Dekker E, de Rooij SEJA, Willemsen JMR, Vogt L, Schouten J, Portegies P, Schmand BA, Geurtsen GJ, ter Stege JA, Klein Twennaar M, van Eck-Smit BLF, de Jong M, Richel DJ, Verbraak FD, Demirkaya N, Visser I, Ruhe HG, Nieuwkerk PT, van Steenwijk RP, Dijkers E, Majoie CBLM, Caan MWA, Su T, van Lunsen HW, Nievaard MAF, van den Born BJH, Stroes ESG, Mulder WMC (2014) Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 59(12):1787–1797. https://doi.org/10.1093/cid/ciu701 CrossRefPubMedGoogle Scholar
- Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, Nishi N, Yamauchi A, Katoh S, Matsukawa A, Kuchroo V, Hirashima M (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127(1):78–88. https://doi.org/10.1016/j.clim.2008.01.006 CrossRefPubMedGoogle Scholar
- Tandon R, Chew GM, Byron MM, Borrow P, Niki T, Hirashima M, Barbour JD, Norris PJ, Lanteri MC, Martin JN, Deeks SG, Ndhlovu LC (2014) Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retrovir 30(7):654–664. https://doi.org/10.1089/AID.2014.0004 CrossRefPubMedGoogle Scholar
- The Human Protein Atlas (n.d.) http://www.proteinatlas.org/ENSG00000168961-LGALS9/tissue. Accessed 23 Aug 2016
- Vagberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H et al (2015) Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. PLoS One 10(8):e0135886. https://doi.org/10.1371/journal.pone.0135886 CrossRefPubMedPubMedCentralGoogle Scholar
- Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JLK, Marovich MA, Slike BM, DeGruttola V, Shiramizu B, for the SEARCH 011 Protocol Team (2013) HIV DNA reservoir increases risk for cognitive disorders in cART-naive patients. PLoS One 8(7):e70164. https://doi.org/10.1371/journal.pone.0070164 CrossRefPubMedPubMedCentralGoogle Scholar
- Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, el-Sadr W, Price RW, For the INSIGHT SMART Study Group (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75(10):864–873. https://doi.org/10.1212/WNL.0b013e3181f11bd8 CrossRefPubMedPubMedCentralGoogle Scholar
- Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, Spudich S, Underwood J, Zetterberg H, Gisslén M (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17(8):761–770. https://doi.org/10.1080/14737159.2017.1341313 CrossRefPubMedGoogle Scholar
- Yoshida H, Imaizumi T, Kumagai M, Kimura K, Satoh C, Hanada N, Fujimoto K, Nishi N, Tanji K, Matsumiya T, Mori F, Cui XF, Tamo W, Shibata T, Takanashi S, Okumura K, Nakamura T, Wakabayashi K, Hirashima M, Sato Y, Satoh K (2001) Interleukin-1beta stimulates galectin-9 expression in human astrocytes. Neuroreport 12(17):3755–3758CrossRefGoogle Scholar